Blood-Based RNA Signature May Predict Alzheimer’s Symptoms Years Before Onset
In a study involving nearly 2,400 participants, a 34-circular RNA signature outperformed plasma pTau217 in predicting progression to symptomatic Alzheimer's disease.
In a study involving nearly 2,400 participants, a 34-circular RNA signature outperformed plasma pTau217 in predicting progression to symptomatic Alzheimer's disease.
Biodesix and Vanderbilt have partnered to develop an AI-powered lung cancer risk test that combines blood-based and imaging biomarkers, with initial data to be presented at RSNA 2026 and commercial launch targeted for 2028.
10x Genomics and Fred Hutchinson Cancer Center have launched a multi-project collaboration to study single cell and spatial profiling for cancer diagnostics, including biomarkers in bladder cancer and residual disease detection in AML.
Mayo Clinic and Thermo Fisher Scientific have launched Precure, a joint venture to analyze one million biospecimens using multi-omics data and AI for early disease biomarker discovery.
Read MoreA University of Oxford study of 275,000 patients found that tracking trends in 23 routine blood tests over time improved cancer risk prediction in those with unexplained weight loss, compared to single test results.
Read MoreThe investigational PANXEON liquid biopsy detected early-stage pancreatic cancer with 87% sensitivity and low false-positive rates in a multi-center study of nearly 1,800 patients.
Read MoreA Columbia University study finds that combining plasma p-tau217 blood tests with APOE4 genotyping can predict Alzheimer’s symptom onset within three to four years in high-risk, asymptomatic individuals.
Read MoreGeneral practitioner requests for AMH fertility tests rose more than 13-fold from 2011 to 2021, despite research showing these tests cannot predict natural conception, according to a Flinders University study of 1.4 million health records.
Read More5Q Spectra plans to launch the Prostate Dx blood test, designed to help assess prostate cancer risk after elevated PSA results and potentially reduce unnecessary biopsies.
Read MoreLabcorp has acquired MLM Medical Labs, expanding its central laboratory network to four continents and strengthening biomarker and specialty testing capabilities for clinical trials, according to a company announcement.
Read MoreAI models analyzing routine H&E slides can identify genomic alterations and immune patterns in NSCLC, supporting biomarker discovery and patient stratification, according to studies to be presented by Lunit at WCLC 2026.
Read MoreKumamoto University researchers have developed a blood test that analyzes nucleosome structures in cell-free DNA to detect breast cancer recurrence.
Read MoreA study validates Nu.Q NETs H3.1 nucleosomes as independent predictors of 28-day mortality and renal replacement therapy need in sepsis and septic shock, according to VolitionRx.
Read MoreHumanity Health and Quest Diagnostics have launched a biological age analysis add-on for select health profile tests in the US, allowing users to assess aging biomarkers using routine blood samples.
Read MoreA Johns Hopkins study reports that adding three urine biomarkers to standard assessments raises the accuracy of predicting deceased donor kidney transplant success from 80% to 86%.
Read MoreThe FDA has cleared Roche’s Elecsys pTau217 blood test to aid in identifying Alzheimer disease amyloid pathology, marking the first single-biomarker assay for both rule-in and rule-out use on existing lab instruments.
Read MoreThe FDA has cleared the first blood-based Alzheimer’s test authorized for symptomatic adults as young as 40.
Read MoreAmsbio has launched synthetic cell mimic controls for flow cytometry, aiming to improve lot-to-lot consistency and reproducibility in diagnostics and cell therapy manufacturing.
Read More